These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. [Typical migraine, its pathogenesis, symptomatology and treatment]. ASSMANN MJ; STUBER H Med Klin; 1956 Jun; 51(23):983-6. PubMed ID: 13347965 [No Abstract] [Full Text] [Related]
63. [Treatment of migraine and persistent headache with ergotamine tartrate and novocaine aerosols]. TABART J Presse Med (1893); 1950 Nov; 58(76):1351-2. PubMed ID: 14797654 [No Abstract] [Full Text] [Related]
64. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893 [TBL] [Abstract][Full Text] [Related]
65. [Efficacy of dihydroergotamine in ophthalmic hemicrania and glaucoma]. PERSICHETTI C Boll Ocul; 1950 Apr; 29(4):234-50. PubMed ID: 14791680 [No Abstract] [Full Text] [Related]
66. Studies on the venoconstrictor effect of ergot compounds in man. Aellig WH Triangle; 1975; 14(1):39-46. PubMed ID: 1162728 [No Abstract] [Full Text] [Related]
67. Treatment of migraine. GRAHAM JR N Engl J Med; 1955 Nov; 253(18):770-6; contd. PubMed ID: 13266040 [No Abstract] [Full Text] [Related]
68. Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine. GRAHAM JR N Engl J Med; 1954 Jun; 250(22):936-8. PubMed ID: 13165929 [No Abstract] [Full Text] [Related]
69. [Use of the rectal route in treatment of migraine]. FROUCHTMAN R Medicina (Mex); 1954 Feb; 34(693):51-2. PubMed ID: 13153691 [No Abstract] [Full Text] [Related]
70. [Present state of ergotina in migraine]. FUCHS M; BLUMENTHAL LS Arch Med Cuba; 1952 May; 3(3):286-9. PubMed ID: 14934511 [No Abstract] [Full Text] [Related]
71. Migraine: diagnosis and pharmacologic treatment in emergency department. Bounes V; Edlow JA Eur Rev Med Pharmacol Sci; 2011 Feb; 15(2):215-21. PubMed ID: 21434490 [TBL] [Abstract][Full Text] [Related]
72. Dihydroergotamine in the treatment of migraine; preliminary clinical observations. FRIEDMAN MD; FRIEDMAN DA Ohio State Med J; 1945; 41():1099. PubMed ID: 21003955 [No Abstract] [Full Text] [Related]
75. [Clinical experience with a new peripheral vasodilator agent, in which are combined raubasine, and 2 ergot alkaloids in the treatment of peripheral diabetic angiopathy]. Martínez-López JM; Calvo-Fernández R; Garrido-Toro A; Sánchez-Cañaveral F Angiologia; 1973; 25(4):195-8. PubMed ID: 4717702 [No Abstract] [Full Text] [Related]
76. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. Ong JJY; De Felice M Neurotherapeutics; 2018 Apr; 15(2):274-290. PubMed ID: 29235068 [TBL] [Abstract][Full Text] [Related]
77. The use of experimental suppositories in treating refractory migraine. REISMAN EE Am Pract Dig Treat; 1952 Apr; 3(4):308-10. PubMed ID: 14924160 [No Abstract] [Full Text] [Related]
78. [Progress in pain therapy exemplified by migraine. What does withdrawal treatment produce? Possibilities of prevention]. Wörz R Fortschr Med; 1985 Jan; 103(1-2):13-4. PubMed ID: 2857678 [No Abstract] [Full Text] [Related]
79. [Ergotamine-caffeine and dihydroergotamine-caffeine in migraine therapy]. DALSGAARD-NIELSEN T Ugeskr Laeger; 1952 Aug; 114(34):1138-42. PubMed ID: 13015718 [No Abstract] [Full Text] [Related]
80. Ergotamine tolerance in patients with migraine. FRIEDMAN AP; VON STORCH TJ J Am Med Assoc; 1955 Mar; 157(11):881-4. PubMed ID: 13233043 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]